Latest News

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral TYK2 for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Peptide compounders face rising scrutiny as regulators and lawsuits lean on USP <795> and <797>.

As spring travel season approaches, more than 30 countries now appear on the CDC's circulating polio alert list.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid-free with good pain ratings and tolerability.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

FDA approval expands teclistamab plus daratumumab significantly improved survival in the MajesTEC-3 trial.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Tanika Kelly, PhD, MPH, discusses her study finding that greater chronic kidney disease (CKD) severity significantly increases the risk of cognitive impairment, with important implications for how pharmacists counsel and support these patients.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

New research links long COVID taste loss to impaired sweet-bitter-umami signaling, guiding pharmacists on nutrition risks and emerging therapies.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Navepegritide becomes the first and only once-weekly treatment to increase linear growth in children with achondroplasia.